Pulmonary sarcoidosis in children: a follow-up study
Authors:
- N. BlancNBN. Blanc
- M. BouléMBM. Boulé
- B. FaurouxBFB. Fauroux
- K. ChadelatKCK. Chadelat
- L. Boccon-GibodLBL. Boccon-Gibod
- G. TournierGTG. Tournier
- A. ClementACA. Clement
- 1 April 2001
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 17 (4) , 628-635
Abstract
Progression of pulmonary sarcoidosis in children remains poorly documented. The aim of this work was to gather follow-up information on pulmonary outcomes in children with sarcoidosis and to obtain data of relevance to a discussion of the optimal length and regimen of glucocorticoid therapy.In the present study, the authors experience of pulmonary sarcoidosis in 21 children referred to the paediatric pulmonary department over a 10-yr period is reported with a documented follow-up of at least 4 yr. Evaluation of the disease during the follow-up included analysis of clinical manifestations, chest radiographs, pulmonary function tests with measurements of the vital capacity (VC), dynamic lung compliance (CL,dyn), lung transfer for CO (TL,CO), and arterial blood gases, as well as bronchoalveolar lavage (BAL) with determination of total and differential cell counts.After initial evaluation the decision was a careful observation of four children without therapy. Corticosteroid treatment was initiated in 17 children. Analysis of results indicated that after 6–12 months of treatment most clinical manifestations of the disease and chest radiograph abnormalities disappeared, and beneficial effects on VC andTL,COwere apparent. After 18 months of steroids no benefit on pulmonary function tests could be noticed, with mainly persistence of alterations ofCL,dyn. Results of BAL studies documented the presence of an alveolitis with increased lymphocyte populations throughout the follow-up. Relapses were observed in four children during tapering of prednisone; they were not reported after discontinuation of steroid therapy.Taken together data obtained in the presented population can lead to the following suggestions for the management of pulmonary sarcoidosis in children. BAL should be performed at the initial evaluation to document alveolitis; however, nothing seems to be gained from repeating this investigation during follow-up in the absence of specific reasons. Once the decision to initiate glucocorticoid therapy is made, 18 months may be a reasonable treatment duration. Discontinuation of therapy can be decided even if the pulmonary function tests remain abnormal, but the child should then be carefully monitored for a relapse.Keywords
This publication has 26 references indexed in Scilit:
- ATS/ERS/WASOG statement on sarcoidosisEuropean Respiratory Journal, 1999
- Uveitis as a presenting feature of chronic sarcoidosisEuropean Respiratory Journal, 1996
- British Thoracic Society Sarcoidosis study: effects of long term corticosteroid treatment.Thorax, 1996
- ACUTE SARCOID ARTHRITIS: OCCURRENCE, SEASONAL ONSET, CLINICAL FEATURES AND OUTCOMERheumatology, 1995
- Corticosteroids in sarcoidosis: friend or foe?European Respiratory Journal, 1994
- Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993European Respiratory Journal, 1994
- Sarcoidosis associated with nephrocalcinosis in young childrenThe Journal of Pediatrics, 1992
- Sarcoidosis in children: Personal observations on age distributionPediatric Pulmonology, 1989
- Childhood sarcoidosisThe Journal of Pediatrics, 1986
- Ocular Presentation of Sarcoidosis in ChildrenClinical Pediatrics, 1983